返回 
加入收藏
瑞舒伐他汀对阵发性心房颤动患者环肺静脉消融术预后的影响
x
请在关注微信后，向客服人员索取文件
| 篇名： | 瑞舒伐他汀对阵发性心房颤动患者环肺静脉消融术预后的影响 |
| TITLE： | |
| 摘要： | 目的：观察瑞舒伐他汀对阵发性心房颤动（AF）环肺静脉消融术后患者预后的影响。 方法：选取阵发性AF患者75例，按照入院单双号分为观察组（39例）和对照组（36例）。两组患者均接受环肺静脉消融术。对照组患者术后口服华法林钠、胺碘酮、美托洛尔等，并皮下注射低分子肝素钙。观察组患者在对照组基础上给予瑞舒伐他汀钙片10 mg，qd。观察两组患者治疗前后心功能、炎症因子、血脂水平变化，并比较随访结果。 结果：两组患者手术前后左房直径、左室射血分数组间比较，差异无统计学意义（P＞0.05）；两组患者术后心房有效不应期（AERP）均显著延长，且观察组显著长于对照组，差异有统计学意义（P＜0.05）。两组患者术后48 h、1个月血清超敏C反应蛋白、白细胞介素6均显著升高，且对照组显著高于观察组，差异有统计学意义（P＜0.05）；术前及术后3个月，两组患者炎性因子水平比较，差异无统计学意义（P＞0.05）。观察组患者术后1个月三酰甘油、低密度脂蛋白胆固醇显著下降，高密度脂蛋白胆固醇显著上升，与对照组比较，差异均有统计学意义（P＜0.05）。两组患者随访时间均为（23.91±5.28）个月，随访期间观察组患者AF复发率为7.8％，显著低于对照组的13.9％，差异有统计学意义（P＜0.05）；两组患者消融相关性房性心动过速（ATa）、不良反应发生率比较，差异均无统计学意义（P＞0.05）。 结论：瑞舒伐他汀能明显抑制阵发性AF患者机体炎性反应、延长AERP，从而降低AF复发率，具有良好的疗效及安全性。 |
| ABSTRACT： | OBJECTIVE： To observe the effect of rosuvastatin on prognostic of patients with paroxysmal atrial fibrillation （AF） after circumferential pulmonary vein ablation. METHODS： 75 patients with paroxysmal AF were divided into observation group （n＝39） and control group （n＝36） according to the admission single. All patients underwent circumferential pulmonary vein ablation antiarrhythmic treatment. Control group orally received warfarin sodium， amiodarone， metoprolol， and subcutaneous injected low molecular weight heparin. Observation group additionally received 10 mg Rosuvastatin tablet， qd on the basic of contol group. Changes of cardiac function， inflammatory factors， lipid levels in 2 groups before and after treatment were observed， and follow-up results were compared. RESULTS： There was no significant difference in left atrial diameter and left ventricular ejection fraction in 2 groups before and after treatment （P＞0.05）； atrial effective refractory periods （AERP） in 2 groups significantly prolorged， and observation group prolorged more significantly than control group， the difference was statistically significant （P＜0.05）. Serum high sensitivity C-reactive protein， interleukin-6 48 h and 1 month after operation in 2 groups significantly increased， and control group was significantly higher than observation group， the difference was statistically significant （P＜0.05）； before operation and after 3 months of operation， there was no significant difference in inflammatory cytokine levels （P＞0.05）. Triglyceride and low density lipoprotein cholesterol in observation group 1 month after operation significantly decreased， HDL-C significantly increased， there were significant differences （P＜0.05）. Follow-up time was （23.91±5.28） months， AF recurrence was 7.8％， which was significantly lower than control group （13.9％）， the difference was statistically significant （P＜0.05）； and there were no significant differences in ablation-related atrial tachycardia （ATa） and the incidence of adverse reactions between 2 groups （P＞0.05）. CONCLUSIONS： Rosuvastatin can effectively inhibit the inflammatory reaction and prolong the AERP， thereby reducing the recurrence rate of AF， with good efficacy and safety. |
| 期刊： | 2016年第27卷第26期 |
| 作者： | 曾安宁，石建，余吉西，陈荣兴，杨钦宇，蔡冰冰，熊德高 |
| AUTHORS： | ZENG Anning，SHI Jian，YU Jixi，CHEN Rongxing，YANG Qinyu，CAI Bingbing，XIONG Degao |
| 关键字： | 阵发性房颤；环肺静脉消融术；瑞舒伐他汀；心房有效不应期；预后 |
| KEYWORDS： | Paroxysmal atrial fibrillation； Circumferential pulmonary vein ablation； Rosuvastatin； Atrial effective refractory period； Prognostic |
| 阅读数： | 320 次 |
| 本月下载数： | 3 次 |
* 注：未经本站明确许可，任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作！
